Identification and Effects of Skim Milk-Derived Bioactive Antihypertensive Peptides

Abstract

Bioactive peptides are generated during milk fermentation or enzymatic hydrolysis. Lactobacillus (L) helveticus is commonly used to produce some types of fermented milk products. Fermented milk derived bioactive peptides are known to be beneficial in human health. Anti-hypertensive peptides play a dual role in the regulation of hypertension through the production of the vasoconstrictor angiotensin II and its inactivation of the vasodilator bradykinin. MALDI MS/MS, nano-LC/MS/MS and RP-HPLC were used to isolate peptides showing angiotensin converting enzyme inhibition (ACE-I) from 12% fermented skim milk using a combination of L. helveticus and Flavourzyme®. The fermentation procedure facilitated the identification of 133 anti-hypertensive peptides and 75% short chain amino acids, and the three with the highest ACE-I activity reduced blood pressure in a rat model of hypertension. The freeze- dried extract was supplemented in rodent chow. In this study 14-week-old male spontaneously hypertensive rats were fed for 10 weeks with the identified peptides added to chow and compared to controls supplemented with skim milk powder. Blood pressure (BP) decreased significantly (p < 0.05) from 6 to 10 weeks of FS groups (120/65 mmHg) compared with the NFS control groups, where the BP increased significantly (220/150 mmHg) (p < 0.05). The F6 fraction provided bioactive peptides with stronger antihypertensive properties than other fractions. Skim milk fermented by L. helveticus and Flavourzyme® generates several bioactive peptides which have a blood pressure lowering effect in hypertensive disease.

Improving the Sustainability of Processing By-Products: Extraction and Recent Biological Activities of Collagen Peptides

“…Hypertension refers to a clinical syndrome characterized by increased arterial blood pressure (systolic and diastolic) in the body circulation (systolic blood pressure ≥140 mm Hg and diastolic blood pressure ≥90 mm Hg), which may increase the incidence and severity of cardiovascular disease, peripheral arterial disease, heart failure, and stroke with impaired kidney function [89,90]. More than one sixth of the blood pressure-lowering drugs used worldwide are angiotensin I-converting enzyme (ACE) inhibitors, such as captopril, because ACE is the key enzyme in the process of raising blood pressure in humans [91].…”